Diabetic Peripheral Neuropathic Pain
Conditions
Keywords
Peripheral Neuropathic Pain
Brief summary
There is a growing evidence that the d-isomer of methadone is effective in treating neuropathic pain while the l-isomer of methadone is the only effective isomer of methadone for treating somatic pain. This study will examine a combination of different amounts of the d- and l-isomers of methadone specifically tailored to the chronic peripheral neuropathic pain. Non-racemic mixture of methadone isomers will be tested in this pilot efficacy and safety study. This study will evaluate effect of the three doses of the non-racemic mixture of methadone hydrochloride patients with chronic peripheral neuropathic pain compared with a placebo. The study will also examine the minimally effective and maximally tolerated doses of the non-racemic mixture of methadone. Finally, the safety and tolerability of the non-racemic methadone therapy will be evaluated.
Detailed description
Objectives: * To evaluate effect of the three doses of the non-racemic methadone HCl on the metrics of pain intensity in comparison to placebo. * To determine minimally effective and maximally tolerated doses of non-racemic methadone HCl for the treatment of diabetic peripheral neuropathic pain. * To evaluate safety and tolerability of non-racemic methadone HCl therapy. Study Design: This is a pilot efficacy and safety study comprised of two parts. Part I is a double-blind, placebo-controlled, crossover study of three daily doses (15 mg, 30 mg and 40 mg) of non-racemic methadone compared with placebo. Two lower doses (15 mg and 30 mg) will be administered for 1 week. The final dose (40 mg) will be administered for 2 weeks. After receiving three consecutive doses of the assigned drug the subjects will be switched to another regimen. Two 28-day treatment periods will be separated by a 14-day washout (drug-free) interval. Subjects will be randomly assigned to one of the two treatment sequences: Sequence 1: non-racemic methadone HCl (Period 1) followed by Placebo (Period 2); Sequence 2: Placebo (Period 1) followed by non-racemic methadone HCl (Period 2). Subjects completing Part I will be enrolled into the open-label, single-arm extension. Subjects discontinuing the study while on placebo may also be eligible for the enrollment. During the 6-week extension phase (Part II of the study) subjects will be treated with non-racemic methadone HCl with continuous dose titration driven by the clinical response (degree of pain relief) and reported adverse events. The Parts I and II will be separated by a 14-day washout (study drug-free) interval. Number of Patients: Up to fifty (50) subjects diagnosed with neuropathic pain associated with diabetic peripheral neuropathy will be enrolled in the study; approximately 30 subjects are expected to complete Study Part I. Enrollment will be terminated when this completion target is achieved. Study Duration: The duration of Study Part I is approximately 12 weeks, the duration of Study Part II is approximately 6 weeks. A total study duration (including screening and final evaluations) is expected to be approximately 20 weeks.
Interventions
DRUGNon-racemic mixture of methadone HCl
Non-racemic mixture of methadone HCl capsules, 5 mg
Sponsors
MetaPharm, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female 18 years of age or older; * Female with a negative serum βhCG pregnancy test * Female of non-childbearing potential (postmenopausal or surgically sterile) OR female of child-bearing potential agreed to use the protocol-approved contraceptive method * Documented diagnosis of neuropathic pain associated with diabetic peripheral neuropathy for at least 6 months * Average daily pain severity score \>=4 for the seven days prior to randomization (based on an 11-point numerical rating scale where 0= no pain and 10=worst possible pain) * Score \>= 40 mm on the VAS of the Short Form McGill Pain Questionnaire (SF-MPQ) at screening and randomization visits * Stable doses (for at least three weeks) of non-opioid analgesics including NSAIDS, corticosteroids, gabapentin, pregabalin or antidepressants prescribed for the purposes of pain control or pain treatment naïve * Willing to refrain from any pain-relieving drugs other than the protocol-approved rescue medications (acetaminophen, \<= 3 g daily or aspirin \<= 325 mg daily) during the screening phase and the course of the study * Willing to limit alcohol consumption during the study according to protocol requirements * Able to understand and complete study diary and questionnaires * Willing to give informed consent prior to entry into the study
Exclusion criteria
* A documented neuropathy of any cause other than diabetic peripheral neuropathy * A severe intermittent pain for reasons other than radiculopathy (e.g., migraine attacks) * History of head injury and/or increased intracranial pressure * Any neurologic disorder unrelated to diabetic peripheral neuropathy * Non-adequate renal and/or hepatic function as follows: Serum creatinine \> 1.5 x ULN (upper limit of normal range) Liver enzymes (ALT and AST) \> 2 x ULN * Any other know laboratory abnormality that, in the investigator's opinion, would contraindicate study participation * Chronic hepatitis B, hepatitis C, or HIV infection * Abnormal cognition defined as obvious clinical findings of state of arousal, confusion and memory or concentration deficit. * Recent history (within the previous 12 months) of respiratory depression, acute bronchial asthma or hypercarbia, or any other severe pulmonary or respiratory disease * Recent history (within the previous 12 months) of sleep apnea * Any hemostatic disorders or a current treatment with anticoagulants; * Unstable cardiovascular disease or symptomatic peripheral vascular disease * Hypotension: sitting or standing systolic blood pressure \<= 90 mmHg and/or diastolic blood pressure \<= 60 mmHg at screening and/or orthostatic hypotension (defined as a difference between sitting and standing systolic blood pressure \>20 mmHg and/or a difference between sitting and standing diastolic blood pressure \>10 mmHg) * Any clinically important ECG abnormality (including QT interval exceeding 450 ms) * Recent history (within the last 12 months) of risk factors for development of prolonged QT interval, including cardiac hypertrophy, concomitant diuretic use, hypocalcemia, hypomagnesemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in average daily pain scores | From Baseline to Week 4 |
Outcome results
None listed